Free Trial
ASX:AC8

AusCann Group (AC8) Stock Price, News & Analysis

About AusCann Group Stock (ASX:AC8)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
537,446 shs
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
6.79%
Price Target
N/A
Consensus Rating
N/A

Company Overview

AusCann Group Holdings Ltd engages in the development and commercialization of cannabinoid-derived therapeutic products for humans and animals in Australia and internationally. Its principal product includes the novel tetrahydrocannabinol and cannabidiol (THC/CBD), a powder-based hard-shell capsules based on AusCann's Neuvis platform for the treatment of pain and related indications. The company is also involved in the research and development of medicinal cannabis. It offers its products to healthcare professionals and veterinarians. AusCann Group Holdings Ltd is based in West Perth, Australia.

Receive AC8 Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AusCann Group and its competitors with MarketBeat's FREE daily newsletter.

AC8 Stock News Headlines

AusCann Group Holdings Ltd (ACNNF)
2025: Crypto Opportunities You Can’t Afford to Miss
Cryptocurrencies are once again gaining incredible momentum, and savvy investors are positioning themselves to capitalize on this surge in 2025. The question is—will you be among them? With groundbreaking advancements and increasing institutional adoption on the horizon, there's never been a better time to explore the potential gains in crypto. What’s Fueling the Crypto Comeback?
AC8.AX - AusCann Group Holdings Ltd
ACNNF AusCann Group Holdings Ltd
See More Headlines

AC8 Stock Analysis - Frequently Asked Questions

Based on aggregate information from My MarketBeat watchlists, some other companies that AusCann Group investors own include 3D Systems (DDD), Bristol-Myers Squibb (BMY), Johnson & Johnson (JNJ), Workday (WDAY), Zoom Video Communications (ZM), Zynerba Pharmaceuticals (ZYNE) and Ambarella (AMBA).

Industry, Sector and Symbol

Sector
Medical
Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Net Income
$-9,440,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$1.36 million
Book Value
A$0.02 per share

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
0.72
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

This page (ASX:AC8) was last updated on 1/23/2025 by MarketBeat.com Staff
From Our Partners